The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice

Majid Ali, Marzieh Kamjoo, Huw D. Thomas, Suzanne Kyle, Ivanda Pavlovska, Muhammed Babur, Brian A. Telfer, Nicola J. Curtin, Kaye J. Williams

    Research output: Contribution to journal › Article › peer-review

    Fingerprint

    Dive into the research topics of 'The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice'. Together they form a unique fingerprint.

    Pharmacology, Toxicology and Pharmaceutical Science